Oral eplerenone for treatment of chronic central serous chorioretinopathy : a case series

Copyright 2015, SLACK Incorporated.

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 46(2015), 4 vom: 13. Apr., Seite 439-44
1. Verfasser: Salz, David A (VerfasserIn)
Weitere Verfasser: Pitcher, John D 3rd, Hsu, Jason, Regillo, Carl D, Fineman, Mitchell S, Elliott, Kevin S, Vander, James F, Fischer, David H, Spirn, Marc J
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2015
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Journal Article Mineralocorticoid Receptor Antagonists Spironolactone 27O7W4T232 Eplerenone 6995V82D0B
LEADER 01000caa a22002652c 4500
001 NLM248980211
003 DE-627
005 20250218125730.0
007 cr uuu---uuuuu
008 231224s2015 xx |||||o 00| ||eng c
024 7 |a 10.3928/23258160-20150422-06  |2 doi 
028 5 2 |a pubmed25n0829.xml 
035 |a (DE-627)NLM248980211 
035 |a (NLM)25970864 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Salz, David A  |e verfasserin  |4 aut 
245 1 0 |a Oral eplerenone for treatment of chronic central serous chorioretinopathy  |b a case series 
264 1 |c 2015 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 23.10.2015 
500 |a Date Revised 10.04.2022 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Copyright 2015, SLACK Incorporated. 
520 |a BACKGROUND AND OBJECTIVE: To evaluate the effect of oral eplerenone on subretinal fluid, visual acuity, and choroidal thickness in patients with chronic central serous chorioretinopathy (CSCR) 
520 |a PATIENTS AND METHODS: Retrospective review of all patients (14 eyes of 14 patients) monitored for a minimum of 3 months with chronic CSCR who were treated with oral eplerenone in a single multi-physician retina practice. Visual acuity, dilated funduscopic examination, and spectral-domain ocular coherence tomography (OCT) with enhanced depth imaging (EDI) were obtained at each visit. Measurement of subfoveal fluid (SFF) height and choroidal thickness were performed. Two-tailed paired t test was used to calculate statistical significance of pre- and post-treatment variables 
520 |a RESULTS: At 1 month, 10 of 14 eyes had decreased SFF height on OCT and two eyes had complete resolution of SFF. Mean SFF height decreased from 130 µm to 62 µm (P = .05). Mean choroidal thickness decreased from 315 µm to 282 µm (P = .07). Mean visual acuity improved from logMAR 0.41 to 0.40. At 3 months, 13 of 14 (93%) had decreased SFF on OCT, and nine eyes (64%) had complete resolution of SFF. Mean SFF height decreased to 21 µm (P = .004). Mean choroidal thickness decreased to 253 µm (P = .10). Mean visual acuity improved to logMAR 0.28 (P = .02) 
520 |a CONCLUSION: Oral eplerenone may be effective in treating patients with chronic CSCR 
650 4 |a Journal Article 
650 7 |a Mineralocorticoid Receptor Antagonists  |2 NLM 
650 7 |a Spironolactone  |2 NLM 
650 7 |a 27O7W4T232  |2 NLM 
650 7 |a Eplerenone  |2 NLM 
650 7 |a 6995V82D0B  |2 NLM 
700 1 |a Pitcher, John D  |c 3rd  |e verfasserin  |4 aut 
700 1 |a Hsu, Jason  |e verfasserin  |4 aut 
700 1 |a Regillo, Carl D  |e verfasserin  |4 aut 
700 1 |a Fineman, Mitchell S  |e verfasserin  |4 aut 
700 1 |a Elliott, Kevin S  |e verfasserin  |4 aut 
700 1 |a Vander, James F  |e verfasserin  |4 aut 
700 1 |a Fischer, David H  |e verfasserin  |4 aut 
700 1 |a Spirn, Marc J  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Ophthalmic surgery, lasers & imaging retina  |d 2013  |g 46(2015), 4 vom: 13. Apr., Seite 439-44  |w (DE-627)NLM224956647  |x 2325-8179  |7 nnas 
773 1 8 |g volume:46  |g year:2015  |g number:4  |g day:13  |g month:04  |g pages:439-44 
856 4 0 |u http://dx.doi.org/10.3928/23258160-20150422-06  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_40 
912 |a GBV_ILN_63 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_90 
912 |a GBV_ILN_91 
912 |a GBV_ILN_130 
912 |a GBV_ILN_135 
912 |a GBV_ILN_136 
912 |a GBV_ILN_151 
912 |a GBV_ILN_181 
912 |a GBV_ILN_203 
912 |a GBV_ILN_217 
912 |a GBV_ILN_235 
912 |a GBV_ILN_289 
912 |a GBV_ILN_294 
912 |a GBV_ILN_297 
912 |a GBV_ILN_350 
912 |a GBV_ILN_352 
912 |a GBV_ILN_674 
912 |a GBV_ILN_676 
912 |a GBV_ILN_688 
912 |a GBV_ILN_698 
912 |a GBV_ILN_721 
912 |a GBV_ILN_737 
912 |a GBV_ILN_791 
912 |a GBV_ILN_812 
912 |a GBV_ILN_1127 
951 |a AR 
952 |d 46  |j 2015  |e 4  |b 13  |c 04  |h 439-44